DNA damage-mediated induction of a chemoresistant niche.
Gilbert
Luke A
LA
The Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, 02139, USA.
Hemann
Michael T
MT
D000818:Animals; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D018929:Cell Culture Techniques; D002470:Cell Survival; D016922:Cellular Senescence; D017077:Culture Media, Conditioned; D016207:Cytokines / Q000032:analysis / Q000378:metabolism; D004249:DNA Damage; D004317:Doxorubicin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D053614:Janus Kinase 2 / Q000378:metabolism; D008113:Liver Neoplasms / Q000473:pathology; D051379:Mice; D018365:Neoplasm, Residual / Q000378:metabolism / Q000473:pathology; D019899:Paracrine Communication; D013950:Thymus Gland / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases
D017077:Culture Media, Conditioned; D016207:Cytokines; D015850:Interleukin-6; D019715:Tissue Inhibitor of Metalloproteinase-1; D004317:Doxorubicin; D053614:Janus Kinase 2; D048051:p38 Mitogen-Activated Protein Kinases